Pfizer Reports Phase 2 Trial Success for Atirmociclib in Second-Line Metastatic Breast Cancer Treatment

Pfizer has released topline results from its Phase 2 clinical trial evaluating Atirmociclib, a next-generation CDK4 inhibitor, for the treatment of second-line metastatic breast cancer. The study focused on patients whose disease had progressed following first-line therapy. The findings indicate that Atirmociclib met its primary endpoint by demonstrating efficacy in this patient population.

The Phase 2 trial assessed the safety and effectiveness of Atirmociclib in combination with endocrine therapy compared to endocrine therapy alone. Researchers observed improved progression-free survival rates among patients receiving the combination treatment. Secondary endpoints included overall response rate and duration of response, both of which showed favorable outcomes for the experimental group. Pfizer stated that adverse events reported during the trial were consistent with those typically associated with CDK4 inhibitors, and no new safety concerns emerged. These results will inform further development plans for Atirmociclib as a potential therapeutic option for metastatic breast cancer.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 17, 2026

Author

GOAI